HeartBeam shares jumped 72% in premarket trading after the FDA cleared its 12-lead ECG synthesis software for arrhythmia assessment. The cable-free system captures 3D electrical signals and converts them into a full 12-lead ECG. The approval follows a successful appeal of a prior NSE decision and marks a major milestone for the company.